ReviewMolecular neurobiology2026
Reprogramming the Inflammatory Response to Promote Neural Stem Cell Function After Spinal Cord Injury.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) represents a devastating neurological condition characterized by immediate mechanical damage followed by secondary pathological processes, including acute and chronic inflammation, which exacerbate neuronal loss, axonal degeneration, and glial scar formation, ultimately leading to permanent functional deficits. Emerging research highlights the dual nature of inflammation, where timely modulation can shift from a detrimental M1-like phenotype to a regenerative M2-like state, thereby fostering neural stem cell (NSC) survival and neurogenesis. Strategies for reprogramming inflammation include pharmacological interventions like minocycline or resolvins to dampen excessive cytokine storms, biomaterial scaffolds impregnated with anti-inflammatory agents to create supportive niches, and gene therapies targeting NF-κB pathways to promote anti-inflammatory signaling. Additionally, stem cell-based approaches, such as mesenchymal stem cell transplantation, secrete immunomodulatory factors that enhance NSC migration and remyelination while reducing astrogliosis. Preclinical models demonstrate that these reprogramming tactics not only mitigate secondary injury but also amplify NSC-mediated repair, improving motor recovery and sensory function. Clinical translation faces challenges like timing of intervention and personalized immunomodulation, yet holds promise for novel therapeutics. The objective of this review is to synthesize current evidence on reprogramming inflammatory pathways to optimize NSC function in SCI and to propose integrated strategies for advancing regenerative therapies.
Indexed as
Identifiers
41912935What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.